CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Aged
Animals
Antigen Presentation
Antigens, CD1d
/ metabolism
Brain Neoplasms
/ immunology
Cancer Vaccines
/ immunology
Cells, Cultured
Cytotoxicity, Immunologic
Female
Gene Expression Regulation, Neoplastic
Glioblastoma
/ immunology
Humans
Immunotherapy, Adoptive
/ methods
Male
Mice
Mice, SCID
Middle Aged
Natural Killer T-Cells
/ immunology
Neoplasm Transplantation
Tretinoin
/ metabolism
CD1d
Cancer immunotherapy
Glioblastoma
NKT cells
Retinoic acid
Stem-like cell
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
09
05
2020
accepted:
12
10
2020
pubmed:
1
11
2020
medline:
5
5
2021
entrez:
31
10
2020
Statut:
ppublish
Résumé
Glioblastoma is the most common and aggressive type of brain tumor with high recurrence and fatality rates. Although various therapeutic strategies have been explored, there is currently no effective treatment for glioblastoma. Recently, the number of immunotherapeutic strategies has been tested for malignant brain tumors. Invariant natural killer T (iNKT) cells play an important role in anti-tumor immunity. To address if iNKT cells can target glioblastoma to exert anti-tumor activity, we assessed the expression of CD1d, an antigen-presenting molecule for iNKT cells, on glioblastoma cells. Glioblastoma cells from 10 of 15 patients expressed CD1d, and CD1d-positive glioblastoma cells pulsed with glycolipid ligand induced iNKT cell-mediated cytotoxicity in vitro. Although CD1d expression was low on glioblastoma stem-like cells, retinoic acid, which is the most common differentiating agent, upregulated CD1d expression in these cells and induced iNKT cell-mediated cytotoxicity. Moreover, intracranial administration of human iNKT cells induced tumor regression of CD1d-positive glioblastoma in orthotopic xenografts in NOD/Shi-scid IL-2RγKO (NOG) mice. Thus, CD1d expression represents a novel target for NKT cell-based immunotherapy for glioblastoma patients.
Identifiants
pubmed: 33128583
doi: 10.1007/s00262-020-02742-1
pii: 10.1007/s00262-020-02742-1
pmc: PMC8053161
doi:
Substances chimiques
Antigens, CD1d
0
Cancer Vaccines
0
Tretinoin
5688UTC01R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1239-1254Subventions
Organisme : Japan Society for the Promotion of Science
ID : #18H0289
Organisme : Japan Society for the Promotion of Science
ID : #17K16625
Organisme : Japan Society for the Promotion of Science
ID : #19K18379
Références
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. https://doi.org/10.1016/S1470-2045(09)70025-7
doi: 10.1016/S1470-2045(09)70025-7
pubmed: 19269895
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330
doi: 10.1056/NEJMoa043330
pubmed: 15758009
Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64(19):7011–7021. https://doi.org/10.1158/0008-5472.CAN-04-1364
doi: 10.1158/0008-5472.CAN-04-1364
pubmed: 15466194
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396–401. https://doi.org/10.1038/nature03128
doi: 10.1038/nature03128
pubmed: 15549107
Morshead CM, van der Kooy D (2004) Disguising adult neural stem cells. Curr Opin Neurobiol 14(1):125–131. https://doi.org/10.1016/j.conb.2004.01.008
doi: 10.1016/j.conb.2004.01.008
pubmed: 15018948
Sanai N, Alvarez-Buylla A, Berger MS (2005) Neural stem cells and the origin of gliomas. N Engl J Med 353(8):811–822. https://doi.org/10.1056/NEJMra043666
doi: 10.1056/NEJMra043666
pubmed: 16120861
Tivnan A, Heilinger T, Lavelle EC, Prehn JH (2017) Advances in immunotherapy for the treatment of glioblastoma. J Neurooncol 131(1):1–9. https://doi.org/10.1007/s11060-016-2299-2
doi: 10.1007/s11060-016-2299-2
pubmed: 27743144
Zhang H, Chen J (2018) Current status and future directions of cancer immunotherapy. J Cancer 9(10):1773–1781. https://doi.org/10.7150/jca.24577
doi: 10.7150/jca.24577
pubmed: 29805703
pmcid: 5968765
Filley AC, Henriquez M, Dey M (2017) Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 8(53):91779–91794. https://doi.org/10.18632/oncotarget.21586
doi: 10.18632/oncotarget.21586
pubmed: 29207684
pmcid: 5710964
Jackson CM, Lim M (2018) Immunotherapy for glioblastoma: playing chess, not checkers. Clin Cancer Res 24(17):4059–4061. https://doi.org/10.1158/1078-0432.CCR-18-0491
doi: 10.1158/1078-0432.CCR-18-0491
pubmed: 29691293
Migliorini D, Dietrich PY, Stupp R, Linette GP, Posey AD Jr, June CH (2018) CAR T-cell therapies in glioblastoma: a first look. Clin Cancer Res 24(3):535–540. https://doi.org/10.1158/1078-0432.CCR-17-2871
doi: 10.1158/1078-0432.CCR-17-2871
pubmed: 29158268
Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S et al (2018) Potent antitumor efficacy of anti-GD2 CAR T cells in H3–K27M
doi: 10.1038/s41591-018-0006-x
pubmed: 29662203
pmcid: 6214371
Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A et al (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375(26):2561–2569. https://doi.org/10.1056/NEJMoa1610497
doi: 10.1056/NEJMoa1610497
pubmed: 28029927
pmcid: 5390684
Godfrey DI, Le Nours J, Andrews DM, Uldrich AP, Rossjohn J (2018) Unconventional T cell targets for cancer immunotherapy. Immunity 48(3):453–473. https://doi.org/10.1016/j.immuni.2018.03.009
doi: 10.1016/j.immuni.2018.03.009
pubmed: 29562195
Takami M, Ihara F, Motohashi S (2018) Clinical application of iNKT cell-mediated anti-tumor activity against lung cancer and head and neck cancer. Front Immunol 9:2021. https://doi.org/10.3389/fimmu.2018.02021
doi: 10.3389/fimmu.2018.02021
pubmed: 30245690
pmcid: 6137091
Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K et al (2009) A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182(4):2492–2501. https://doi.org/10.4049/jimmunol.0800126
doi: 10.4049/jimmunol.0800126
pubmed: 19201905
Ulanova M, Tarkowski A, Porcelli SA, Hanson LA (2000) Antigen-specific regulation of CD1 expression in humans. J Clin Immunol 20(3):203–211
doi: 10.1023/A:1006689514066
Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC (2003) Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 17(6):1068–1077. https://doi.org/10.1038/sj.leu.2402943
doi: 10.1038/sj.leu.2402943
pubmed: 12764370
Fais F, Tenca C, Cimino G, Coletti V, Zanardi S, Bagnara D et al (2005) CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia 19(4):551–556. https://doi.org/10.1038/sj.leu.2403671
doi: 10.1038/sj.leu.2403671
pubmed: 15744356
Dhodapkar KM, Cirignano B, Chamian F, Zagzag D, Miller DC, Finlay JL et al (2004) Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer 109(6):893–899. https://doi.org/10.1002/ijc.20050
doi: 10.1002/ijc.20050
pubmed: 15027123
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972. https://doi.org/10.1200/JCO.2009.26.3541
doi: 10.1200/JCO.2009.26.3541
pubmed: 20231676
Jurcic JG, Soignet SL, Maslak AP (2007) Diagnosis and treatment of acute promyelocytic leukemia. Curr Oncol Rep 9(5):337–344. https://doi.org/10.1007/s11912-007-0045-9
doi: 10.1007/s11912-007-0045-9
pubmed: 17706161
Ying M, Wang S, Sang Y, Sun P, Lal B, Goodwin CR et al (2011) Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. Oncogene 30(31):3454–3467. https://doi.org/10.1038/onc.2011.58
doi: 10.1038/onc.2011.58
pubmed: 21383690
pmcid: 3955956
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F et al (2005) Intraepithelial CD8
doi: 10.1073/pnas.0509182102
pubmed: 16344461
Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J et al (2005) Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11(4):1467–1473. https://doi.org/10.1158/1078-0432.CCR-04-1869
doi: 10.1158/1078-0432.CCR-04-1869
pubmed: 15746048
Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS et al (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25(18):2586–2593. https://doi.org/10.1200/JCO.2006.09.4565
doi: 10.1200/JCO.2006.09.4565
pubmed: 17577038
Tachibana T, Onodera H, Tsuruyama T, Mori A, Nagayama S, Hiai H et al (2005) Increased intratumor Vα24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 11(20):7322–7327. https://doi.org/10.1158/1078-0432.CCR-05-0877
doi: 10.1158/1078-0432.CCR-05-0877
pubmed: 16243803
Tang B, Wu W, Wei X, Li Y, Ren G, Fan W (2014) Activation of glioma cells generates immune tolerant NKT cells. J Biol Chem 289(50):34595–34600. https://doi.org/10.1074/jbc.M114.614503
doi: 10.1074/jbc.M114.614503
pubmed: 25342742
pmcid: 4263866
Waziri A, Killory B, Ogden AT 3rd, Canoll P, Anderson RC, Kent SC et al (2008) Preferential in situ CD4
doi: 10.4049/jimmunol.180.11.7673
pubmed: 18490770
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760. https://doi.org/10.1038/nature05236
doi: 10.1038/nature05236
pubmed: 17051156
Chalmers AJ (2007) Radioresistant glioma stem cells–therapeutic obstacle or promising target? DNA Repair (Amst) 6(9):1391–1394. https://doi.org/10.1016/j.dnarep.2007.03.019
doi: 10.1016/j.dnarep.2007.03.019
Johannessen TC, Bjerkvig R, Tysnes BB (2008) DNA repair and cancer stem-like cells–potential partners in glioma drug resistance? Cancer Treat Rev 34(6):558–567. https://doi.org/10.1016/j.ctrv.2008.03.125
doi: 10.1016/j.ctrv.2008.03.125
pubmed: 18501520
Batlle E, Clevers H (2017) Cancer stem cells revisited. Nat Med 23(10):1124–1134. https://doi.org/10.1038/nm.4409
doi: 10.1038/nm.4409
pubmed: 28985214
Siddikuzzaman GC, Berlin Grace VM (2011) All trans retinoic acid and cancer. Immunopharmacol Immunotoxicol 33(2):241–249. https://doi.org/10.3109/08923973.2010.521507
doi: 10.3109/08923973.2010.521507
pubmed: 20929432
Liu D, Song L, Brawley VS, Robison N, Wei J, Gao X et al (2013) Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clin Immunol 149(1):55–64. https://doi.org/10.1016/j.clim.2013.06.005
doi: 10.1016/j.clim.2013.06.005
pubmed: 23891738